Log In
Print
BCIQ
Print
Print this Print this
 

TRC105

  Manage Alerts
Collapse Summary General Information
Company Tracon Pharmaceuticals Inc.
DescriptionHuman chimeric mAb against endoglin (CD105; ENG)
Molecular Target Endoglin (CD105) (ENG)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$10.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today